Global Orphan Drugs Market Research Report 2023: Market to Reach $415.2 Billion by the End of 2028 - Premium Pricing of Orphan Drugs and Increasing Collaborations/Licensing Agreements Bolsters Growth

Key Facts

• Orphan drugs have paved the way for the treatment of the many unmet clinical and therapeutic needs of patients with orphan and rare diseases such as Gaucher's disease, Pompe disease, cystic fibrosis, Hunter syndrome, tuberous sclerosis complex and chronic myelogenous leukemia.
• Growth factors include multiple post-market safety and efficacy clinical trials and the commission of potential orphan drugs through patient networks such as the European Organization for Rare Diseases (EURORDIS).
• The main growth factors in this emerging regional market are patient awareness programs, global connectivity through rare disease patient organizations and the availability of orphan drugs through joint collaborations.
• Report Includes 33 data tables and 46 additional tables Overview and an up-to-date analysis of the global markets for orphan drugs (ODs) for rare diseases treatment Analyses of the global market trends, with historical market revenue data (sales figures) from 2021 to 2022, estimates for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028 Highlights of the current and future market potential of orphan drugs, along with a detailed analysis of the market drivers, restraints, and opportunities Estimate of the actual market size and revenue forecast for the global orphan drugs market, and its corresponding market share analysis based on the product type, therapeutic area, and region Analysis of market growth opportunities with a holistic review of Porter's five forces model and PESTLE analyses considering the micro and macroeconomic factors prevailing in the marketplace Discussion of sustainability trends and factors in the orphan drugs market, with emphasis on consumer attitudes, ESG score analysis, future of ESG, case study, and the ESG practices followed Analyses of the novel therapeutic applications of orphan drugs in rare and orphan diseases as well as examination of the regulatory framework, patents, and recent innovations in the industry Review of the current status and trends in clinical trials for the development of drugs in rare diseases among the three registries from the U.S., EU and Japan Discussion of successful orphan medicinal products, rising influence of pharmacogenomics in the ODs market, information on specific rare diseases for which orphan drugs exist Assessment of the most promising therapeutic areas in the industry and leading orphan drugs in these areas Overview of the industry structure for orphan drugs, pricing and reimbursement policies, COVID-19 impact, and market share analysis of the leading manufacturers of orphan drugs along with their SWOT analyses Company profiles of major players within the industry, including AstraZeneca Plc, Eisai Co. Ltd., Bristol Myers Squibb and Pfizer Inc. Company Profiles Abbvie Inc. Astellas Pharma Inc. Astrazeneca Plc Bristol Myers Squibb * Eisai Co. Ltd.

Click To Read Full Article